ClinicalTrials.gg
RecruitingNCT07541430Updated Oct 21, 2026

A Study in Adults With Desmoid Tumors

A Phase 2 interventional study of ES014 and ES014 in Desmoid Tumor, sponsored by Elpiscience (Suzhou) Biopharma, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Elpiscience (Suzhou) Biopharma, Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 21, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.

02

Conditions studied

  • Desmoid Tumor

Browse trials for

Keywords

  • CD39
  • TGF-β
  • CD39xTGF-β
03

In context

Desmoid Tumors

71 studies on the registry are indexed under Desmoid Tumors; 21 are open to participants now.

This study's planned enrollment of 50 is above the median of 44 across 47 interventional studies indexed under Desmoid Tumors.

Browse Desmoid Tumors studies →

Lead sponsor

Elpiscience (Suzhou) Biopharma, Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) confirmed desmoid tumor.
  • 2)Within 12 months prior to enrollment, meeting any of the following: Tumor target lesion growth ≥ 20% or appearance of new lesions;Desmoid tumor-related pain not adequately controlled by non-opioid medications.
  • 3)Meeting any of the following conditions: Subjects with recurrence or disease progression after at least one (including surgery, radiotherapy, or systemic therapy, etc.); Treatment-naive subjects who are deemed suitable for the study drug by the investigator.
  • 4)Presence of at least one (according to v1.1).
  • 5) (ECOG) Performance Status (PS) score of 0-2.
  • 6) of at least 12 weeks.
  • 7)Adequate hematologic, hepatic, renal and coagulation functions per protocol.
  • 8)Male and female subjects of must be willing to completely abstain or agree to use a highly effective method of .

Exclusion criteria

Exclusion Criteria:

  • 1)Any prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β.
  • 2)Receipt of any agents or devices within 4 weeks prior to the first dose of study drug.
  • 3)Prior treatment with any of the following:

    1. Anticancer therapy, including chemotherapy, tyrosine kinase inhibitors (TKIs), etc., within 28 days or 5 half-lives (whichever is shorter, but not less than 14 days) prior to the first dose of study drug.
    2. For subjects who have received radiotherapy, a of at least 2 weeks (limb radiation) or 4 weeks (chest, brain, or visceral organ radiation) is required before the start of study drug administration.
    3. Traditional Chinese medicine (TCM) and proprietary Chinese medicines: if the package insert or investigator deems them to have clear anti-tumor effects, a 14-day washout is required. Other TCM and proprietary Chinese medicines do not require a washout.
  • 4)Prior or autologous bone marrow transplantation or solid organ transplantation.
  • 5)Previous treatment-related toxicities unresolved to ≤ Grade 1, with the exception of alopecia (any grade), ≤ Grade 2 peripheral sensory neuropathy, and long-standing irreversible toxicities at the investigator's discretion.
  • 6)Major surgery within 4 weeks prior to the first dose of study treatment.
  • 7) therapies within 4 weeks prior to the first dose of study treatment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Part1, Arm 1

    Drug: ES014

  • Experimental
    Part1, Arm 2

    Drug: ES014

Interventions

  • DrugES014

    ES014 is administered via intravenous infusion, 700mg once every 14 days.

  • DrugES014

    ES014 is administered via intravenous infusion, 1400mg once every 14 days.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) by IRC according to RECIST 1.1

    Time frame: 1-3 years

Secondary outcomes

  1. Evaluate the safety and tolerability of ES014 in adult patients with desmoid tumors

    The assessment is based on the changes in AE, SAE, as well as safety and laboratory evaluation parameters.

    Time frame: 1-3 years

  2. The efficacy of ES014 in adult patients with desmoid tumors

    Based on the IRC according to RECIST v1.1, the efficacy of ES014 in adult patients with hard desmoid tumors was assessed.

    Time frame: 1-3 years

  3. Evaluate the PK of ES014

    Evaluate based on the PK concentration of ES014

    Time frame: 1-3 years

  4. Evaluate the immunogenicity of ES014

    By observing the generation process of ADA in ES014 for evaluation

    Time frame: 1-3 years

  5. The efficacy of ES014 in adult patients with desmoid tumors

    Based on the DOR evaluated by the researchers , the efficacy of ES014 in adult patients with hard desmoid tumors was assessed.

    Time frame: 1-3 years

  6. The efficacy of ES014 in adult patients with desmoid tumors

    Based on the DCR by the researchers , the efficacy of ES014 in adult patients with hard desmoid tumors was assessed.

    Time frame: 1-3 years

  7. The efficacy of ES014 in adult patients with desmoid tumors

    Based on the FPS by the researchers , the efficacy of ES014 in adult patients with hard desmoid tumors was assessed.

    Time frame: 1-3 years

  8. The efficacy of ES014 in adult patients with desmoid tumors

    Based on the OS by the researchers , the efficacy of ES014 in adult patients with hard desmoid tumors was assessed.

    Time frame: 1-3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 21, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Oct 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 30, 2026→Apr 24, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Start date Apr 30, 2026→Apr 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07541430
Lead sponsor
Elpiscience (Suzhou) Biopharma, Ltd.
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Apr 24, 2026
Primary completion
Jan 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Jiayu Song
Contact
ClinicalOperation@elpiscience.com
(+86) 21 50651310

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014

Start the discussion